Gandhi Aravind P, Thakur J S, Gupta Madhu, Soundappan Kathirvel, Goel Kapil, Singh Gopal, Singh Tarundeep
Department of Community Medicine, All India Institute of Medical Sciences, Nagpur, India.
Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Med Res. 2024;160(3&4):371-378. doi: 10.25259/IJMR_1014_2024.
Background & objectives Studies on the effects of COVID-19 vaccination among pregnant women in Asian settings, more specifically in India, are scarce. The present study evaluated the feto-maternal outcomes among Indian pregnant women who received the COVID-19 vaccine. Methods A prospective cohort study was undertaken among 430 pregnant women from two primary health centres (PHC) in Chandigarh, India during 2021-2022. The feto-maternal outcomes evaluated in the study included abortions, live birth/stillbirth, term/pre-term/post-term delivery, mode of delivery (normal vaginal/caesarean section/forceps), birth weight and intrauterine growth retardation. Results Of the 430 study participants, 295 pregnant women received COVID-19 vaccines, with an uptake rate of 68.6 per cent. Majority of vaccinated women (280- who completed the study) were in their second trimester (133, 47.5%), while 92 (32.9%) were in their third, and 55 (19.6%) were in their first trimester when they were enrolled in the study. Neonatal intensive care unit (NICU) admission was significantly lower among the vaccinated pregnant women, while other feto-maternal and neonatal outcomes were similar between vaccinated and unvaccinated pregnant women. Interpretation & conclusions The findings of this study suggest COVID-19 vaccination in pregnant women in India might be safe, in terms of feto-maternal outcomes.
在亚洲地区,尤其是印度,关于新冠疫苗接种对孕妇影响的研究很少。本研究评估了接种新冠疫苗的印度孕妇的母婴结局。方法:2021年至2022年期间,对印度昌迪加尔两个初级卫生保健中心(PHC)的430名孕妇进行了一项前瞻性队列研究。该研究评估的母婴结局包括流产、活产/死产、足月/早产/过期产、分娩方式(正常阴道分娩/剖宫产/产钳助产)、出生体重和宫内生长受限。结果:在430名研究参与者中,295名孕妇接种了新冠疫苗,接种率为68.6%。大多数接种疫苗的妇女(280名完成研究)在孕中期(133名,47.5%),而92名(32.9%)在孕晚期,55名(19.6%)在孕早期纳入研究。接种疫苗的孕妇入住新生儿重症监护病房(NICU)的比例显著较低,而接种疫苗和未接种疫苗的孕妇之间的其他母婴和新生儿结局相似。解读与结论:本研究结果表明,就母婴结局而言,印度孕妇接种新冠疫苗可能是安全的。